16 results on '"Gong, Haihong"'
Search Results
2. Deregulated microRNA-22-3p in patients with sepsis-induced acute kidney injury serves as a new biomarker to predict disease occurrence and 28-day survival outcomes
- Author
-
Zhang, Hui, Che, Lin, Wang, Yanfei, Zhou, Haiyan, Gong, Haihong, Man, Xiaofei, and Zhao, Qian
- Published
- 2021
- Full Text
- View/download PDF
3. The link between smoking, emphysema, and fibrosis: A retrospective cohort study.
- Author
-
Zhai, Liying, Gong, Haihong, and Yu, Wencheng
- Subjects
- *
RISK assessment , *STATISTICAL correlation , *SMOKING , *PULMONARY emphysema , *MULTIPLE regression analysis , *INTERSTITIAL lung diseases , *RETROSPECTIVE studies , *LONGITUDINAL method , *KAPLAN-Meier estimator , *LOG-rank test , *ODDS ratio , *RESEARCH , *COMPARATIVE studies , *SURVIVAL analysis (Biometry) , *CONFIDENCE intervals , *PULMONARY fibrosis , *PROPORTIONAL hazards models , *DISEASE risk factors - Abstract
Introduction: The presence of emphysema is common in patients with interstitial lung disease (ILD), which is designated as combined pulmonary fibrosis and emphysema (CPFE). This study aimed to examine the association between smoking, emphysema, and fibrosis in ILD patients. Methods: A total of 800 patients hospitalized for ILD at the affiliated hospital of Qingdao University, Shandong, Qingdao, China, from December 2012 to December 2020 were included in our retrospective cohort study. Participants were divided into CPFE and non-CPFE groups. The patients' clinical presentations and radiographic and laboratory findings were reviewed and compared. The two groups were then divided and compared based on smoking status. Kaplan-Meier survival analysis with log-rank testing and multivariable Cox proportional hazards regression analysis were used to compare all-cause mortality. Results: Emphysema was present in 188 (23.5%) ILD patients. Smoking was associated with increased odds of CPFE (adjusted odds ratio, AOR=2.13; 95% CI: 1.33–3.41, p=0.002). The CPFE patients had a comparable risk of death to non- CPFE patients (adjusted hazard ratio, AHR=0.89; 95% CI: 0.64–1.24, p=0.493). Smoking was not a risk prognostic factor in the whole group (AHR=1.34; 95% CI: 0.90–1.99, p=0.152) or the CPFE group (AHR=0.90; 95% CI: 0.43–1.86, p=0.771). However, a significant prognostic difference between smokers and non-smokers was found in the non-CPFE group (AHR=1.62; 95% CI: 1.02–2.58, p=0.042). In ILD patients, smoking pack-years were weakly correlated with total centrilobular emphysema (CLE) scores and total fibrosis scores (TFS), but not with total emphysema scores (TES); TFS were weakly correlated with TES. Conclusions: CPFE did not affect the prognosis of ILD. Smoking was a risk but not a prognostic factor for CPFE. However, smoking was associated with worse survival in non-CPFE patients. There was an intricate association among smoking, emphysema, and fibrosis in ILD patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. An open label, multicenter clinical trial that investigated the efficacy and safety of leuprorelin treatment of central precocious puberty in Chinese children
- Author
-
Luo, Xiaoping, Hou, Ling, Zhong, Yan, You, Cheng, Yang, Yu, Wu, Xian, Li, Pin, Zhou, Shasha, Qiu, Wenjuan, Zhang, Huiwen, Liu, Ying, Qian, Ye, Luo, Feihong, Cheng, Ruoqian, Hu, Yuhua, Gong, Haihong, Wang, Qing, Xu, Zhuangjian, Du, Hongwei, Lu, Feiyu, Fu, Junfen, Chen, Xuefeng, Wang, Winston, and Guo, Ziheng
- Published
- 2021
- Full Text
- View/download PDF
5. Diffuse pulmonary lymphangiomatosis: A rare case report in an adult
- Author
-
Yu, Wencheng, Mi, Liyun, Cong, Jinpeng, Cheng, Wei, Chen, Yunqing, and Gong, Haihong
- Published
- 2019
- Full Text
- View/download PDF
6. The distribution of myeloid-derived suppressor cells subsets and up-regulation of programmed death-1/PD-L1 axis in peripheral blood of adult CAP patients.
- Author
-
Gong, Haihong, Zhao, Jingquan, Xu, Wenshuai, Wan, Yinghua, Mu, Xiangdong, and Zhang, Mingqiang
- Subjects
- *
PROGRAMMED cell death 1 receptors , *MYELOID-derived suppressor cells , *SUPPRESSOR cells , *MONONUCLEAR leukocytes , *REGULATORY T cells , *COMMUNITY-acquired pneumonia , *CANCER cells - Abstract
Background: Myeloid-derived suppressor cells (MDSCs) have been reported to expand and have a potent ability in the expansion of regulatory T cells in malignant and infectious disease. The current study was performed to investigate the role of MDSCs and possible immune mechanisms in dampening immune responses of community acquired pneumonia (CAP). Methods: This was a single-center cross-sectional study. The distribution of MDSCs subsets, the PD-1/PD-L1(L2) level of MDSCs subsets and Tregs in the peripheral blood of adult CAP patients and healthy control were measured by flow cytometry analysis. Results: Peripheral blood mononuclear cells (PBMCs) from 63 adult CAP patients contained an elevated frequency of both G-MDSC (4.92±0.30 vs 2.25±0.21,p<0.0001) and M-MDSC (19.40±1.30 vs 9.64±0.57,p<0.001) compared to healthy controls. Treg in the peripheral blood of CAP patients exhibited increased expression of PD-1 and CTLA-4, accompanied by no difference of their frequency. Moreover, up-regulated expression of PD-L1 on MDSC subsets in the peripheral blood of CAP patients was also revealed. Of note, the frequency of circulating MDSCs subset displayed a positive correlation with neutrophil count percentage in blood in CAP patients. Conclusions: In summary, the significant expansion of circulating MDSCs subsets and the up-regulated expression of PD-1/PD-L1 level in CAP patients may suggest the possible involvement of PD-1/PD-L1axis in MDSCs mediated immune regulation on Treg at least partially in CAP patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Long-Term Efficacy and Safety of Recombinant Human Growth Hormone in Children Born Small for Gestational Age.
- Author
-
Wu, Wei, Gong, Chunxiu, Li, Yuchuan, Hu, Yuhua, Gong, Haihong, Fu, Junfen, Huang, Ke, Li, Pin, and Luo, Xiaoping
- Subjects
SMALL for gestational age ,PITUITARY dwarfism ,HUMAN growth hormone ,GROWTH of children ,SOMATOMEDIN ,CHINESE people ,SOMATOTROPIN receptors - Abstract
There is a lack of long-term data on the benefit of growth hormone (GH) treatment in Chinese children born small for gestational age (SGA). This study was conducted to assess the long-term efficacy and safety of GH treatment in children born SGA. One hundred and twenty prepubertal SGA children who did not achieve catch-up growth with height remained less than –2 standard deviations (SD) below gender-specific height were enrolled in this two-year, randomized, dose-comparative study followed by an extension study of up to 10 years. Daily subcutaneous injections of 0.23 mg/kg/week [low-dose (LD) group] or 0.46 mg/kg/week [high-dose (HD) group] somatropin were given for 104 weeks. Dosing in the extension study was≤0.46 mg/kg/week. The main outcome measures were change in height SD score (ΔHT-SDS), height velocity, insulin-like growth factor (IGF)-1, and IGF-1/IGF binding protein-3 (IGFBP-3) molar ratio. ΔHT-SDS at week 104 was 0.91±0.53 and 1.52±0.64 in the LD and HD groups (intergroup p<0.0001), respectively, and continued in an upward trend throughout the extension study, remaining above+2 for those who received treatment for a total of 7 years or more. At week 104, significant improvements were observed in height velocity, IGF-1 SDS, and IGF-1/IGFBP-3 molar ratio. Adult HT-SDS was –0.81±1.68 for boys and –0.82±1.05 for girls (p=0.9837). Glucose metabolism and thyroid function were within the normal reference range throughout treatment. Long-term recombinant human GH treatment was tolerable and effective at improving height in children born SGA. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. New Insights on Obstructive Sleep Apnea and Postacute Sequelae of SARS-CoV-2 Infection.
- Author
-
Zhai, Liying, Gong, Haihong, and Yu, Wencheng
- Subjects
- *
SLEEP apnea syndromes , *SARS-CoV-2 , *DISEASE complications , *INFECTION - Published
- 2024
- Full Text
- View/download PDF
9. A Randomized Controlled Phase 3 Study on the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Idiopathic Short Stature.
- Author
-
Yuan, Jinna, Fu, Junfen, Wei, Haiyan, Zhang, Gaixiu, Xiao, Yanfeng, Du, Hongwei, Gu, Wei, Li, Yanhong, Chen, Linqi, Luo, Feihong, Zhong, Yan, and Gong, Haihong
- Subjects
HUMAN growth hormone ,SHORT stature ,GROWTH of children ,AGE ,SOMATOTROPIN - Abstract
Background: To evaluate the safety and efficacy of daily somatropin (Jintropin
® ), a recombinant human growth hormone, in prepubertal children with ISS in China. Methods: This study was a multicenter, randomized, controlled, open-label, phase 3 study. All subjects were randomized 3:1 to daily somatropin 0.05 mg/kg/day or no treatment for 52 weeks. A total of 481 subjects with a mean baseline age of 5.8 years were enrolled in the study. The primary endpoint was change in (△) height standard deviation score (HT-SDS) for chronological age (CA). Secondary endpoints included △height from baseline; △bone age (BA)/CA; △height velocity (HV) and △insulin-like growth factor 1 (IGF-1 SDS). Results: △HT-SDS at week 52 was 1.04 ± 0.31 in the treatment group and 0.20 ± 0.33 in the control group (P < 0.001). At week 52, statistical significance was observed in the treatment group compared with control for △height (10.19 ± 1.47 cm vs. 5.85 ± 1.80 cm; P < 0.001), △BA/CA (0.04 ± 0.09 vs. 0.004 ± 0.01; P < 0.001), △HV (5.17 ± 3.70 cm/year vs. 0.75 ± 4.34 cm/year; P < 0.001), and △IGF-1 SDS (2.31 ± 1.20 vs. 0.22 ± 0.98; P < 0.001). The frequencies of treatment-emergent adverse events (TEAEs) were similar for the treatment and the control groups (89.8% vs. 82.4%); most TEAEs were mild to moderate in severity and 23 AEs were considered study-drug related. Conclusions: Daily subcutaneous administration of somatropin at 0.05 mg/kg/day for 52 weeks demonstrated improvement in growth outcomes and was well tolerated with a favorable safety profile. Trial Registration: ClinicalTrials.gov (identifier: NCT03635580). URL: https://clinicaltrials.gov/ct2/show/NCT03635580 [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
10. Effect of IRAK-M on Airway Inflammation Induced by Cigarette Smoking.
- Author
-
Gong, Haihong, Liu, Tao, Chen, Wei, Zhou, Weixun, and Gao, Jinming
- Subjects
- *
SMOKING , *AIRWAY (Anatomy) , *INFLAMMATION , *LIPOPOLYSACCHARIDES , *DENDRITIC cells , *DISEASES - Abstract
Background. IRAK-M, negatively regulating Toll-like receptor, is shown the dual properties in the varied disease contexts. We studied the effect of IRAK-M deficiency on cigarette smoking- (CS-) induced airway inflammation under acute or subacute conditions in a mouse model. Methods. A number of cellular and molecular techniques were used to detect the differences between IRAK-M knockout (KO) and wild type (WT) mice exposed to 3-day or 7-week CS. Results. Airway inflammation was comparable between IRAK-M KO and WT mice under 3-day CS exposure. Upon short-term CS exposure and lipopolysaccharide (LPS) inhalation, IRAK-M KO mice demonstrated worse airway inflammation, significantly higher percentage of Th17 cells and concentrations of proinflammatory cytokines in the lungs, and significantly elevated expression of costimulatory molecules CD40 and CD86 by lung dendritic cells (DCs) or macrophages. Conversely, 7-week CS exposed IRAK-M KO mice demonstrated significantly attenuated airway inflammation, significantly lower concentrations of proinflammatory cytokines in the lungs, significantly increased percentage of Tregs, and lower expression of CD11b and CD86 by lung DCs or macrophages. Conclusions. IRAK-M plays distinctive effect on CS-induced airway inflammation, and influences Treg/Th17 balance and expression of costimulatory molecules by DCs and macrophages, depending on duration and intensity of stimulus. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
11. Diffuse pulmonary lymphangiomatosis: A rare case report in an adult.
- Author
-
Wencheng Yu, Liyun Mi, Jinpeng Cong, Wei Cheng, Yunqing Chen, Haihong Gong, Yu, Wencheng, Mi, Liyun, Cong, Jinpeng, Cheng, Wei, Chen, Yunqing, and Gong, Haihong
- Published
- 2019
- Full Text
- View/download PDF
12. Respiratory motor output during an inspiratory capacity maneuver is preserved despite submaximal exercise.
- Author
-
Zhang, Dong, Gong, Haihong, Lu, Gan, Guo, Hongxi, Li, Ruifa, Zhong, Nanshan, Polkey, M.I., and Luo, Yuanming
- Subjects
- *
RESPIRATION , *LUNG volume , *EXERCISE intensity , *DIAPHRAGM (Anatomy) , *ELECTROMYOGRAPHY , *NEURAL physiology - Abstract
Highlights: [•] Diaphragm EMG reached a plateau during either 80% or 60% constant work rate exercise tests. [•] Plateau of the diaphragm EMG during exercise does not mean that there is neural inhibition. [•] Inspiratory capacity maneuver seldom entails a maximal effort even in well trained normal subjects. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
13. The clinical association of programmed death-1/PD-L1 axis, myeloid derived suppressor cells subsets and regulatory T cells in peripheral blood of stable COPD patients.
- Author
-
Zhang M, Wan Y, Han J, Li J, Gong H, and Mu X
- Subjects
- Humans, B7-H1 Antigen metabolism, CTLA-4 Antigen, Programmed Cell Death 1 Receptor, T-Lymphocytes, Regulatory metabolism, Myeloid-Derived Suppressor Cells metabolism, Pulmonary Disease, Chronic Obstructive
- Abstract
Background: Myeloid-derived suppressor cells (MDSCs) have crucial immunosuppressive role in T cell dysfunction in various disease processes. However, the role of MDSCs and their impact on Tregs in COPD have not been fully understood. The aim of the present study is to investigate the immunomodulatory role of MDSCs and their potential impact on the expansion and function of Tregs in COPD patients., Methods: Peripheral blood samples were collected to analyze circulating MDSCs, Tregs, PD-1/PD-L1 expression to assess the immunomodulatory role of MDSC and their potential impact on the expansion and function of Treg in COPD. A total of 54 COPD patients and 24 healthy individuals were enrolled in our study. Flow cytometric analyses were performed to identify granulocytic MDSCs (G-MDSCs), monocytic MDSCs (M-MDSCs), Tregs, and the expression of PD-1/PD-L1(L2) on MDSCs and Tregs in peripheral blood., Results: Our results revealed a significantly higher percentage of G-MDSCs and M-MDSCs ( p < 0.001) in COPD patients compared to the healthy controls. Additionally, a significantly higher proportion of peripheral blood Tregs was observed in COPD patients. Furthermore, an increased expression of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) on Tregs ( p < 0.01) was detected in COPD patients. The expression of PD-1 on CD4
+ Tcells and Tregs, but not CD8+ Tcells, was found to be increased in patients with COPD compared to controls. Furthermore, an elevated expression of PD-L1 on M-MDSCs ( p < 0.01) was also observed in COPD patients. A positive correlation was observed between the accumulation of M-MDSCs and Tregs in COPD patients. Additionally, the percentage of circulating M-MDSCs is positively associated with the level of PD-1 (r = 0.51, p < 0.0001) and CTLA-4 (r = 0.42, p = 0.0014) on Tregs in COPD., Conclusion: The recruitment of MDSCs, accumulation of Tregs, and up-regulation of CTLA-4 on Treg in COPD, accompanied by an increased level of PD-1/PD-L1, suggest PD-1/PD-L1 axis may be potentially involved in MDSCs-induced the expansion and activation of Treg at least partially in COPD., Competing Interests: The authors declare that they have no competing interests., (© 2024 Zhang et al.)- Published
- 2024
- Full Text
- View/download PDF
14. Long-acting PEGylated growth hormone in children with idiopathic short stature.
- Author
-
Luo X, Zhao S, Yang Y, Dong G, Chen L, Li P, Luo F, Gong C, Xu Z, Xu X, Gong H, Du H, Hou L, Zhong Y, Shi Q, Chen X, Chen X, Xu L, Cheng R, Su C, Ma Y, Xu L, Zhang L, and Lu H
- Subjects
- Body Height physiology, Child, Growth Disorders drug therapy, Growth Hormone therapeutic use, Humans, Insulin-Like Growth Factor Binding Protein 3, Insulin-Like Growth Factor I metabolism, Polyethylene Glycols adverse effects, Recombinant Proteins adverse effects, Human Growth Hormone therapeutic use
- Abstract
Objective: To evaluate the safety and efficacy of weekly PEGylated-recombinant human growth hormone (PEG-rhGH) in children with idiopathic short stature (ISS) in China., Design and Methods: This was a multicenter, phase II study in which all subjects were randomized 1:1:1 to weekly s.c. injections of PEG-rhGH 0.1 (low-dose (LD) group) or 0.2 mg/kg/week (high-dose (HD) group) or control for 52 weeks. The primary end point was change (Δ) in height s.d. score (HT-SDS) from baseline to week 52. Secondary end points were height velocity (HV), bone maturity, insulin-like growth factor-1 (IGF-1) SDS, and IGF-1/insulin-like growth factor-binding protein-3 (IGFBP-3) molar ratio., Results: A total of 360 children with ISS were recruited in the study (n = 120 in each group). At week 52, ΔHT-SDS was 0.56 ± 0.26, 0.98 ± 0.35, and 0.20 ± 0.26 in the LD, HD, and control groups, respectively (within-group P < 0.0001; intergroup P < 0.0001). Statistically significant values of ΔHV, IGF-1, IGF-1/IGFBP-3 ratio, and IGF-1 SDS at week 52 from baseline were observed in both treatment groups (P < 0.0001). There were clear dose-dependent responses for all auxological variables. PEG-rhGH was well tolerated throughout the treatment period with treatment-emergent adverse events (TEAEs) reported in 86.5%, 84.6%, and 91.3% of children in the HD, LD, and control groups, respectively. The incidence of TEAEs was similar in all treatment groups despite the difference in doses. A total of 27 (8.7%) children experienced drug-related TEAEs., Conclusion: Fifty-two-week treatment with PEG-rhGH 0.1 or 0.2 mg/kg/week achieved significant improvement in HT-SDS and other growth-related variables, including HV, IGF-1 SDS, and IGF-1/IGFBP-3 ratio, in a dose-dependent manner. Both doses were well tolerated with similar safety profiles.
- Published
- 2022
- Full Text
- View/download PDF
15. The pharmacokinetic and pharmacodynamic properties and short-term outcome of a novel once-weekly PEGylated recombinant human growth hormone for children with growth hormone deficiency.
- Author
-
Liang Y, Zhang C, Wei H, Du H, Zhang G, Yang Y, Zhang H, Gong H, Li P, Song F, Xu Z, He R, Zhou W, Zheng H, Sun L, and Luo X
- Subjects
- Child, Humans, Insulin-Like Growth Factor I, Polyethylene Glycols, Recombinant Proteins, Dwarfism, Pituitary, Human Growth Hormone
- Abstract
Objectives: To investigate the pharmacokinetics (PK) and pharmacodynamics (PD) of Y-shape branched PEGylated recombinant human growth hormone (YPEG-rhGH) and evaluate its short-term efficacy and safety in children with growth hormone deficiency (GHD)., Methods: A total of 43 children with GHD from 12 sites in China were enrolled in this randomized, multicenter, active-controlled, double-blind (YPEG-rhGH doses) trial. Patients were randomized 1:1:1:1 to 100, 120, and 140 μg/kg/week of YPEG-rhGH groups and daily rhGH 35 μg/kg/day groups. The treatment lasted 12 weeks. The primary outcome was the area under the curve of the change of insulin-like growth factor-1 (IGF-1). The secondary outcome was the height velocity (HV) increment at week 12., Results: A dose-dependent response of maximum plasma concentration (C
max ) and area under the concentration-time curves from 0 to 168 hours (AUC0-168h ) were observed for YPEG-rhGH. The ratio of Cmax and the ratio of AUC0-168h from the first to the last dosing were 1.09~1.11 and 1.22~1.26 respectively. A YPEG-rhGH dose-dependent increase in area under effect curve (AUEC) of IGF-1 fold change was observed. Model-derived mean IGF-1 SDS was in the normal range for all three YPEG-rhGH doses. At week 12, HV was 7.07, 10.39, 12.27 cm/year, and 11.58 cm/year for YPEG-rhGH 100, 120, and 140 μg/kg/week and daily rhGH respectively. Adherence and safety were consistent with the profile of daily rhGH. No related serious adverse events were reported., Conclusion: The PK/PD suggests that YPEG-rhGH is suitable for the once-weekly treatment of pediatric GHD. YPEG-rhGH 120 ~ 140 μg/kg/week provides the closest HV increment with similar safety and tolerability compared to daily rhGH 35 μg/kg/day in children with GHD., Clinical Trial Registration: ClinicalTrials.gov, identifier [NCT04513171]., Competing Interests: LS is the president of Xiamen Amoytop Biotech Co., Ltd. RH and WZ are employees of Xiamen Amoytop Biotech Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Liang, Zhang, Wei, Du, Zhang, Yang, Zhang, Gong, Li, Song, Xu, He, Zhou, Zheng, Sun and Luo.)- Published
- 2022
- Full Text
- View/download PDF
16. Neuromuscular electrical stimulation improves exercise capacity in adult patients with chronic lung disease: a meta-analysis of English studies.
- Author
-
Gong H, Jiang Q, Shen D, and Gao J
- Abstract
Background: Neuromuscular electrical stimulation (NMES) has been suggested as an alternative rehabilitative therapy to enhance exercise performance and skeletal muscle function in adult patients with chronic lung disease. However, the results of individual studies have been inconsistent. We performed a meta-analysis to evaluate the effectiveness of NMES with regard to increasing exercise capacity, quadriceps strength, muscle mass, cross-sectional area, and quality of life and decreasing dyspnea in adult patients with chronic lung disease., Methods: A systematic search was conducted of the PubMed, Cochrane Library and EMBASE databases for randomized controlled trials (RCTs) published in English-language journals before January 2018. Data were extracted using standardized forms, and the weighted mean difference (WMD) or standardized mean difference (SMD) with 95% confidence intervals (CIs) was calculated., Results: Eleven RCTs involving 368 patients were included in this meta-analysis. The pooled results showed that NMES significantly improved the 6-min walk distance (WMD: 37.93 m, 95% CI: 19.53-56.33 m; P<0.0001; P for heterogeneity =0.11; I
2 =47%) but not the incremental shuttle walk test (WMD: 18.18 m, 95% CI: -79.41 to 115.77 m, P=0.72; P for heterogeneity <0.0001, I2 =94%) or endurance shuttle walk test (ESWT) (WMD: 96.73 m, 95% CI: -45.58 to 239.03 m, P=0.18; P heterogeneity =0.22, I2 =34%). Moreover, NMES was associated with a significant improvement in quadriceps strength (SMD: 1.14, 95% CI: 0.86-1.43, P<0.00001; P heterogeneity =0.02, I2 =58%)., Conclusions: This systemic review and meta-analysis provided evidence supporting the beneficial role of NMES in improving exercise capacity in patients with chronic respiratory disease., Competing Interests: Conflicts of Interest: The authors have no conflicts of interest to declare.- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.